Loading
Sorafenib was the first systemic drug to lengthen survival in advanced liver cancer, adding almost three months compared with placebo, and remained the only option for a decade.
Phase 3 placebo-controlled trial of 602 patients with advanced hepatocellular carcinoma and preserved liver function (Child-Pugh A) randomised to sorafenib 400 mg twice daily or placebo.
Median overall survival was 10.7 versus 7.9 months (hazard ratio 0.69), time to radiological progression 5.5 versus 2.8 months, with response in only 2 percent; diarrhoea, weight loss and hand-foot skin reaction were the main toxicities.
Sorafenib became the reference standard against which lenvatinib, atezolizumab-bevacizumab and durvalumab-tremelimumab were tested, and remains an option where immunotherapy is unsuitable.
Shares Sorafenib, Advanced hepatocellular carcinoma (BCLC C).
Shares Sorafenib, Advanced hepatocellular carcinoma (BCLC C).
Shares Sorafenib, Advanced hepatocellular carcinoma (BCLC C).
Shares Sorafenib, Advanced hepatocellular carcinoma (BCLC C).
Shares Sorafenib, Advanced hepatocellular carcinoma (BCLC C).
Shares Advanced hepatocellular carcinoma (BCLC C), New England Journal of Medicine.